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Background: Surgery is considered to be the first line treatment for solid tumours. Recently, retrospective studies reported that
general anaesthesia was associated with worse long-term cancer-free survival when compared with regional anaesthesia. This has
important clinical implications; however, the mechanisms underlying those observations remain unclear. We aim to investigate the
effect of anaesthetics isoflurane and propofol on prostate cancer malignancy.
Methods: Prostate cancer (PC3) cell line was exposed to commonly used anaesthetic isoflurane and propofol. Malignant potential
was assessed through evaluation of expression level of hypoxia-inducible factor-1a (HIF-1a) and its downstream effectors, cell
proliferation and migration as well as development of chemoresistance.
Results: We demonstrated that isoflurane, at a clinically relevant concentration induced upregulation of HIF-1a and its
downstream effectors in PC3 cell line. Consequently, cancer cell characteristics associated with malignancy were enhanced, with
an increase of proliferation and migration, as well as development of chemoresistance. Inhibition of HIF-1a neosynthesis through
upper pathway blocking by a PI-3K-Akt inhibitor or HIF-1a siRNA abolished isoflurane-induced effects. In contrast, the intravenous
anaesthetic propofol inhibited HIF-1a activation induced by hypoxia or CoCl2. Propofol also prevented isoflurane-induced HIF-1a
activation, and partially reduced cancer cell malignant activities.
Conclusions: Our findings suggest that modulation of HIF-1a activity by anaesthetics may affect cancer recurrence following
surgery. If our data were to be extrapolated to the clinical setting, isoflurane but not propofol should be avoided for use in cancer
surgery. Further work involving in vivo models and clinical trials is urgently needed to determine the optimal anaesthetic regimen
for cancer patients.
Cancer is a leading cause of death worldwide and its incidence is
set to increase from 12.7 million new cases in 2008 to an estimated
26 million by 2030 (Bray et al, 2012). As surgery remains the
mainstay treatment option for most solid tumours, there is valid
impetus to define the factors within the perioperative period that
have the potential to affect the longer-term outcome of patients
after surgery, particularly in terms of cancer recurrence. One such
factor, subject to much speculation in recent years, is anaesthetics
and/or anaesthetic technique.
Accumulating clinical evidence indicates that general anaes-
thesia combined with regional anaesthesia is associated with
improved outcomes in patients undergoing surgery for a variety of
cancers when compared with general anaesthesia alone (Exadaktylos
et al, 2006; Biki et al, 2008b; Christopherson et al, 2008;
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Lin et al, 2011). A much-cited example is a retrospective
study involving 225 patients with prostate cancer undergoing
radical prostatectomy in which it was reported that general
anaesthesia combined with epidural anaesthesia was associated
with a 57% lower recurrence rate (Biki et al, 2008a) when
compared with general anaesthesia alone. It is argued that general
anaesthesia using inhalational agents is immunosuppressive,
whereas the use of regional anaesthesia helps attenuating surgical
stress and the associated neuroendocrine responses, perhaps
accounting for the observed association between use of regional
anaesthesia and a higher disease-free survival rate (Biki et al,
2008b; Welden et al, 2009; Gottschalk et al, 2010; Lin et al, 2011;
de Oliveira et al, 2011; Gottschalk et al, 2012). However, other
mechanisms beyond the immunosuppressive effect of general
anaesthetics may also play an important contributory role in this
process.
One such mechanism involves the action of anaesthetics on a
specific cell signalling pathway. Inhaled anaesthetics such as xenon
have been shown to upregulate transcription factors, for example,
hypoxia-inducible factor-1a (HIF-1a), a phenomenon that appears
to underpin the cytoprotective effects of these agents on organs
experiencing hypoxic injury (Ma et al, 2009). Conversely, the
intravenous anaesthetic, propofol, has been shown to have the
opposite effect, suppressing HIF-1a protein synthesis in an oxygen
tension-dependent manner (Takabuchi et al, 2004b).
Hypoxia induces crucial biological responses in tumour growth
(Liao & Johnson, 2007). HIF-1a has been identified as a key
regulator of this process, which activates a spectrum of down-
stream genes to promote cell proliferation (Terraneo et al, 2010;
Wang et al, 2011), angiogenesis (Ban et al, 2010; Eisinger-
Mathason and Simon, 2010) and metastasis (Burrows et al, 2011).
Cancer cells take advantage of the ensuing phenotypic responses,
not only in promoting cell survival in the harsh tumour
environment but also in gaining competitive advantage over
neighbouring, healthy cells. High levels of HIF-1a within a tumour
have been associated with poorer patient prognosis and it has been
considered as a potential therapeutic target in cancer (Semenza,
2003b). It is therefore rational to predict that the further
upregulation of HIF-1a by an anaesthetic would compound or
even enhance its effect of promoting malignant behaviour in
cancer cells, whereas the use of an agent such as propofol which
has been shown to inhibit HIF-1a activity might prove helpful in
bringing about the opposite effect.
Using a well-established prostate cancer (PC3) cell line, the aim
of this study was to investigate the impact of anaesthetic-induced
HIF-1a activation in cancer cells, comparing the inhalational
anaesthetic isoflurane with the intravenous anaesthetic, propofol,
alone and in combination.
MATERIALS AND METHODS
Cell culture. Human authenticated prostate adenocarcinoma PC3
cancer cell line, derived from an advanced androgen-independent
bone-metastasised prostate cancer, were cultured in monolayer in
75-cm2 tissue culture flasks (VWR, Leistershire, UK). They were
maintained at 37 1C in humidified air balanced with 5% CO2 in
RPMI 1640 medium (GIBCO, Invitrogen, Paisley, UK) supple-
mented with 10% heat-inactivated fetal calf serum (Thermo
Scientific, Epsom, UK), 2mM L-glutamine and 100Uml 1
penicillin–streptomycin (Invitrogen). Culture medium was
replaced every 48 h.
Isoflurane exposure. Before gas exposure, PC3 cells were cultured
at 1 106 per ml density on 30-mm2 Petri dishes (VWR,
Leistershire, UK) and used 24 h later when they were 80%
confluent. Cell media was replaced either with fresh RPMI 1640
medium supplemented with serum and then placed in 1.5 l
purpose-built airtight, temperature-controlled chambers equipped
with inlet and outlet valves and an internal electric fan used to
provide continuous delivery and mixture of gases. For cell cycle
study, cell media was without serum as the cell cycle can be
synchronized through serum deprivation (Gopinathan et al, 2014).
The chamber was connected to calibrated flow meters and an in-
line vaporiser used to deliver the desired composition (Datex gas
monitor, Helsinki, Finland) of isoflurane (0.5–2.0%) (Abbott
Laboratories, Maidenhead, UK) in 21% oxygen and 5% CO2
balanced with nitrogen (BOC, Guildford, UK). The chamber was
pre-flushed with the aforementioned gas mixture to ensure that a
stable gas composition was achieved, and a closed system was
established to prevent leakage. Gas treatment was given at the
desired isoflurane concentration for 2 h at 371C. The cells were
then removed and the serum-free medium was replaced with full-
culture medium and the Petri dishes were returned to a standard
incubator containing humidified air and 5% CO2 at 37
1C for
further analysis. Cells used as the naı¨ve control group were placed
in an identical gas chamber containing 21% oxygen and 5% CO2
balanced with nitrogen at 37 1C. Cells were analysed at different
time points ranging from 0–24 h post gas exposure.
Propofol treatment. Two formulations of propofol were used,
dissolved in either 10% intralipid (the formulation for clinical use,
from Astra-Zeneca, London, UK) or in DMSO (Sigma-Aldrich,
Dorset, UK). Before treatment, PC3 cells were cultured at the
density of 1 106 per ml on a 30-mm2 Petri dishes, as described
above.
In the case of propofol in intralipid formation, propofol was
diluted with PC3 medium to a stock concentration of 0.4mgml 1.
On the day of the experiment, the stock solution of propofol was
diluted with PC3 serum-free medium to the desired concentrations
(0.5–10 mgml 1). For the intralipid control, 20% intralipid was
diluted in cell medium to recreate the amount of intralipid in the
highest 10 mgml 1 dose of propofol being used. In the case of
propofol in DMSO, prior to incubating the cells, propofol was
dissolved to clinically relevant concentrations (1–4mgml 1) with
PC3 serum-free medium. The DMSO control corresponded to the
amount of DMSO (0.05%) in the 4 mgml 1 dose of propofol.
Propofol-supplemented medium was then added to the cell
cultures for 2 h. Cells were then washed with Dulbeccos
phosphate-buffered saline (DPBS; GIBCO, Invitrogen) and
replaced with normal PC3 cell culture medium. For exposure to
both isoflurane and propofol, cells were treated with propofol
(0–10 mgml 1 in either lipid or DMSO)-supplemented media and
then exposed to 2% isoflurane for 2 h. Following exposure,
propofol medium was replaced with full PC3 cell medium and
cells were harvested 24 h following anaesthetic treatment.
Cobalt chloride-mediated HIF-1a induction. A 1-mM stock
solution of cobalt chloride (CoCl2) was prepared by dissolving
CoCl2 powder (Sigma-Aldrich, Dorset, UK) in dH2O, this stock
solution was then further diluted to a concentration of 100 mM
with serum-free propofol (0–4mgml 1 in intralipid)-supplemen-
ted PC3 medium. Before treatment, PC3 cells were cultured at a
density of 1 106 per ml on 30-mm2 Petri dishes, as described
above. Complete medium was then replaced with CoCl2 and
propofol-supplemented medium for 6 h. Cells were harvested
immediately after exposure for western blotting.
Hypoxic HIF-1a induction. Cells were placed in a gas chamber as
described earlier and exposed to a mixture of 1% oxygen balanced
in nitrogen, and 5% CO2 for 18 h at 37
1C in the presence
(1–4 mgml 1) or absence of propofol. The cells were then
immediately harvested for western blotting.
siRNA-mediated HIF-1a knockdown. PC3 cells were transfected
with high-quality human-specific HIF-1a siRNA (Qiagen, Sussex, UK):
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sense strand 50-GAAGAACUAUGAACAUAAATT-30; antisense
strand 50-UUUAUGUUCAUAGUUCUUCCT-30). A scrambled
non-sense siRNA (Qiagen) without specific gene-silencing activity
was used as a negative control. Transfection was achieved using
lipofectamine RNAi MAX (Invitrogen). PC3 cells were cultured at
the density of 0.4 106 per ml and treated with siRNA targeting
human HIF-1a or scrambled siRNA dissolved in siRNA suspen-
sion buffer supplement with lipofectamine which was administered
to PC3 cells in a dose of 20 nM. Cells were incubated with siRNA
for 6 h at 37 1C in humidified air containing 5% CO2, after which
the cells were washed with DPBS, then serum-free medium was
added followed by isoflurane gas exposure and/or propofol
exposure and in conjuction with the chemotherapeutic agent
Docetaxel (see below).
Treatment with a chemotherapeutic agent. A typical anti-mitotic
chemotherapeutic agent for prostate cancer, Docetaxel (DTX), was
used in conjuction with isoflurane and propofol treatments on PC3
cells. Twenty-four hours post isoflurane exposure or propofol
treatment with or without siRNA pre-treatment, DTX (Tocris,
Bristol, UK) of 1-mM stock solution was diluted to a concentration
of 10–100 mM with PC3 medium. Cell medium was then replaced
with DTX-supplemented medium for 24 h.
PI3K and MEK inhibition. PC3 cells were cultured at a density of
1 106 per ml in 30-mm2 petri dishes and then treated with either
a selective inhibitor of phosphatidylinositol 3 kinase (PI3K),
LY294002 (Cell signaling, Hitchin, UK) or a selective inhibitor of
mitogen-activated protein/extracellular-regulated kinase (MAPK/
ERK), U0126 (Cell signaling) for 16 h at 37 1C in a humidified
atmosphere containing 5% CO2 prior to isoflurane and/or propofol
exposure. Both chemicals were dissolved in sterile DMSO to create
a stock concentration of 10mM. For the final solution, they were
further diluted with serum-free culture medium to the final
working concentration of 50 mM, with concentration of DMSO
being 0.05%. Cells were harvested for western blotting immediately
after anaesthetic exposure.
Western blotting. Control or treated PC3 cells described above
were washed with ice-cold PBS buffer and lysed on ice by physical
disruption using a cell scraper in 20mM Tris-HCl (pH 7.5), 150mM
NaCl, 1mM Na2EDTA, 2mM EGTA, 1% Triton, 2.5mM Na4P2O7,
1mM beta-glycerophosphate, 1mM Na3VO4, 1 mgml
 1 leupeptin,
1mM phenyl methane sulphonyl fluoride and 1mM dithiothreitol
cell lysis buffer (Cell Signalling). The samples were centrifuged at
13 000 r.p.m. for 30min at 4 1C, and the supernatant was collected.
Total protein concentration was quantified using the Bradford
protein assay (Bio-Rad Laboratories, Hercules, CA, USA) and
protein extracts were normalised for protein content to 40 mg per
sample. Protein extracts were added to sodium dodecyl sulphate
(SDS) sample buffer (Invitrogen) at 1 : 3 ratio, heated for 10min at
95 1C and then loaded on a NuPAGE 4–12% Bis-Tris gel
(Invitrogen) for electrophoresis. Following electrophoresis, they
were transferred to a polyvinylidenedifluoride (PVDF) membrane
and blocked overnight in 5% non-fat powdered milk in 0.1%
Tween 20/tris-buffered saline (TBST) at 4 1C. The membranes were
then probed with the following primary antibodies: mouse anti-
HIF-1a (BD Biosciences, San Jose, CA, USA); rabbit anti-Bcl-2
(Abcam, Cambridge, UK); rabbit anti-HIF-1b (Cell Signaling);
rabbit anti-phospho-Akt (Cell Signaling); mouse anti-phospho-
ERk (Cell Signaling), in 5% non-fat dry milk in TBST overnight at
4 1C, followed by HRP-conjugated anti-mouse or anti-rabbit
secondary antibodies (Cell Signaling) for 1 h. The loading control
was the constitutively expressed protein a-tubulin (Sigma-Aldrich,
Dorset, UK). The blots were washed with TBST for 5min three
times followed by one wash with TBS and were visualised using the
enhanced chemiluminescence (ECL) system (Santa Cruz, Dallas,
TX, USA). The protein bands were captured with an image
processor using the Syngene GeneSnap software (Syngene,
Cambridge, UK) and the intensity of the bands corresponding to
the protein expression level was measured using GeneTools
software (Syngene, Cambridge, UK). Results were normalised to
levels of the housekeeping protein a-tubulin and expressed as ratio
of the control for data analysis.
Immunocytochemistry. PC3 cells were fixed in 4% paraformal-
dehyde for 10min, rinsed in PBS (Sigma-Aldrich) two times for
5min, permeabilised with 0.1% Triton X-100 in PBS (PBS-T) for
10min and washed twice for 5min. Blocking was carried out at
room temperature for 1 h using 10% normal goat serum (Vector
Laboratories, Peterborough, UK).
Cells were incubated overnight at 4 1C in blocking solution
containing one of the following antibodies: rabbit anti-HIF-1a
(Novus Biologicals, Littleton, CO, USA), rabbit anti-VEGF
(Abcam), mouse anti-Ki-67 (Dako, Cambridge, UK), mouse anti-
cytochrome c (BD Biosciences, San Jose, CA, USA), mouse anti-
cyclin D (Abcam), mouse anti-cyclin E (Abcam). Following three
PBS rinses, cells were incubated for 2 h in PBS-T containing one of
the following secondary antibodies: Rhodamine-conjugated
donkey anti-rabbit IgG (Millipore, Oxford, UK), Fluorescein
isothiocyanate (FITC)-conjugated donkey anti-rabbit IgG
(Millipore) or FITC-conjugated anti-rabbit (Millipore), followed
by final PBS rinses and coverslipping with Vectorshield fluores-
cence medium containing 40,6-diamidino-2-phenylindole (DAPI)
(Vector Laboratories). In the case of double labeling, the following
combinations of antibodies were used for this study: HIF-1a/
VEGF, HIF-1a/Ki-67, HIF-1a/cyclin D and HIF-1a/cyclin E, PC3
cells were incubated with the first primary antibody overnight,
followed by the first secondary antibody, and then the second
primary antibody and the second secondary antibody. Images of 10
high-power fields (HPFs) at  20 magnification were obtained
using an AxioCam digital camera (Zeiss, Welwyn Garden City,
UK) mounted on an Olympus BX60 microscope (Olympus,
Middlesex, UK) with Zeiss KS-300 software (Zeiss). Images were
captured under identical exposure settings and final assessments
were conducted under blinded conditions. In the case of HIF-1a,
HIF-1a/VEGF, HIF-1a/ki67 and cytochrome-c staining, images
were used for qualitative analysis. For ki67 staining, eight
representative fields were randomly selected and the mean pixel
intensities for ki67-positive cells were measured through ImageJ
1.35 software (NIH, Bethesda, MD, USA). Ki67-positive cells were
then presented as a percentage of the total number of DAPI-
positive cells.
Cell viability test (MTT Assay). The viability of cells was assessed
by using a colorimetric 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-
2H-tetrazolium bromide (MTT); (Merck KGaA, Darmstadt,
Germany) assay. MTT was diluted with minimum essential
mediumþEarle’s L-glutamine 1 (MEM) (GIBCO, Invitrogen)
to a concentration of 0.5mgml 1. Cells were then incubated with
0.5mgml 1 of MTT for 2 h at 37 1C in a humidified atmosphere
containing 5% CO2. The solution was then carefully aspirated out
and 1ml of DMSO, (Fisher Scientific, Leicestershire, UK) was
added to dissolve the purple-coloured formazan particles and form
a homogeneous purple colour. The samples from duplicate wells
were transferred to a 96-well plate, and the absorbance of dissolved
formazan crystals was spectrophotometrically assessed at a
wavelength of 595 nm, using an Mrx microplate reader (Dynex
Technologies, Chantilly, VA, USA) and presented in arbitrary
units. Viability was defined as the ratio of the optical density of
formazan in the treated group against that in the control.
Scratch assay. The scratch assay (wound-healing assay) was
performed for assessing tumour cell migration, as previously
described (Liang et al, 2007). After cultured cells became confluent
in 24-well plates, one artificial gap created by a sterile plastic
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micropipette tip (1000 ml) to generate a uniform gap that was
devoid of adherent cells. Gap closure was monitored with digital
camera images taken in a phase-contrast microscope equipped
with a digital camera (Olympus CK30, Tokyo, Japan). Images were
analysed using ImageJ. The same scratch was analysed before and
24 h after treatment using ImageJ 1.35 software. Wound
healing was quantified as the mean percentage of the remaining
cell-free area compared with the area of the initial wound
(Hu & Verkman, 2006).
Enzyme-linked immunosorbent assay (ELISA). Cultured cell
medium with or without treatments was harvested for MMP-2 and
MMP-9 measurements determined with ELISA kits (R&D Systems,
Oxon, UK) following the manufacturer’s instructions.
Statistical analysis. All numerical data were expressed as
mean±s.d. Comparison between different treatments was
analysed by one-way ANOVA followed by post hoc Student–
Newman–Keuls test using GraphPad Prism (GraphPad Software,
La Jolla, CA, USA). A P-value o0.05 was considered to be
statistically significant.
RESULTS
Isoflurane induced persistent HIF-1a expression and transloca-
tion at clinically relevant concentrations. In order to distinguish
the effects of isoflurane exposure on HIF-1a protein levels, PC3
cells were exposed to 0.5–2% isoflurane for 2 h, and cells were
harvested at 0, 2, 4, 8 and 24 h after gas exposure and examined
using western blotting and immunocytochemistry. Isoflurane
exposure induced a marked increase in HIF-1a protein level in a
time-dependent (Figure 1A) and a dose-dependent manner
(Figure 1B). Specifically, exposure to 2% isoflurane triggered
significant upregulation of HIF-1a protein levels, which was
observed from 4 h (3.33±0.59 vs 1.00 of NC, Po0.001; Figure 1A)
post gas exposure, maintained at 8 h (3.19±0.62 vs 1.00 of NC,
Po0.001; Figure 1A) and was maximally increased 24 h post
exposure (3.74±0.81 vs 1.00 of NC, Po0.001; Figure 1A).
Furthermore, isoflurane-induced activation of HIF-1a expression
was dose-dependent with significant increases after exposure with
1.5% isoflurane (2.11±0.58 vs 1.00 of NC, P¼ 0.041; Figure 1B)
and 2% isoflurane (3.20±0.92 vs 1.00 of NC, Po0.001, Figure 1B).
Moreover, it was observed that 24 h following isoflurane exposure
there was a distinct translocation of HIF-1a from the cytoplasm
into the nucleus (compared with the naı¨ve control) where it
initiates downstream gene expression as a transcriptional regulator
(Figure 1C). It is important to note that protein levels of HIF-1b
remained unchanged after isoflurane exposure both in the time
course (P¼ 0.9672, Figure 1D) and the dose-response experiments
(P¼ 0.6425, Figure 1E).
Propofol inhibited activation of HIF-1a induced by various
stimulants. To test the effect of propofol on HIF-1a expression,
co-intervention experiments were performed with clinically
relevant concentrations of propofol (p4 mgml 1) and HIF-1a
inducers: hypoxia, CoCl2 or isoflurane. Exposure times varied
depending on the experiment performed. Cells were harvested
either immediately after the co-intervention experiments
(propofol and hypoxia or CoCl2), or at different time points
for propofol alone (0–24 h), or at 24 h post-anaesthetic exposure
for propofol and isoflurane. In order to exclude any effects of
the propofol vehicle, DMSO and intralipid controls were used in
these experiments as well as the naı¨ve control. Exposure to hypoxia
significantly increased HIF-1a protein levels when compared with
the naı¨ve control (3.14±0.50 vs 1.00 of naive, Po0.01; Figure 2A);
an effect that was abrogated following co-exposure to hypoxia and
propofol in a dose-dependent manner (1.38±0.64-fold of naı¨ve for
propofol at 2mgml 1 and 1.16±0.26-fold of naı¨ve for propofol at
4 mgml 1 vs 3.14±0.50-fold of naı¨ve for isoflurane alone, Po0.01;
Figure 2A). Similar results were observed for cells treated with both
CoCl2 and propofol. CoCl2 was shown to induce HIF-1a activation
(3.33±0.41 vs 1.00 of naive, Po0.01, Figure 2B) and propofol
negated this effect (1.85±0.30-fold of naı¨ve for propofol at
1 mgml 1, 1.15±0.30-fold of naı¨ve for propofol at 2 mgml 1 and
0.87±0.34-fold of naı¨ve for propofol at 4mgml 1 vs 3.33±0.41-fold
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Figure 1. Effect of isoflurane exposure on expression and translocation of HIF-1a in cultured human prostate cancer cells (PC3 cells). Cultured
cells were exposed to 0.5–2% for 2 h and were harvested immediately or 2–24 h after exposure for western blotting. (A, B) A time- and
concentration-dependent increase in HIF-1a expression after isoflurane exposure; (C) immunostaining further revealed isoflurane exposure
promoted the translocation of HIF-1a from cytoplasm to nucleus where its downstream effects are initiated; (D, E) HIF-1b expression was
unchanged after exposure to isoflurane. Results are expressed as mean±s.d.; *Po0.05; **Po0.001 vs naı¨ve control. Bar¼ 25mm.
Prostate cancer cell malignancy BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2014.426 1341
of naı¨ve for isoflurane alone, Po0.01; Figure 2B). Most
importantly, propofol abolished 2% isoflurane-induced HIF-1a
expression in a dose-dependent manner both when dissolved in
lipid (1.95±0.28-fold of naı¨ve for propofol at 2mgml 1 P¼ 0.04,
0.89±0.59-fold of naı¨ve for propofol at 4mgml 1 and 0.82±0.48-
fold of naı¨ve for propofol at 10 mgml 1 vs 3.12±0.24-fold of naı¨ve
for isoflurane alone, Po0.01; Figure 2C) and when dissolved in
DMSO (2.25±0.38-fold of naı¨ve for propofol at 1 mgml 1
P¼ 0.048, 1.27 ±0.35-fold of naı¨ve for propofol at 2mgml 1
and 1.11±0.21-fold of naı¨ve for propofol at 4 mgml 1 vs
3.01±0.20-fold of naı¨ve for isoflurane alone, Po0.01; Figure 2D).
Propofol and HIF-1a siRNA inhibited isoflurane-induced VEGF
upregulation and cell proliferation. We next investigated
whether isoflurane increased VEGF levels and cell proliferation
in PC3 cells and, furthermore, whether HIF-1a inhibition through
siRNA treatment and propofol treatment abrogated these effects.
PC3 cells (with or without siRNA pre-treatment) were either
exposed to 2% isoflurane alone for 2 h or in combination with
4mgml 1 of propofol for 2 h. Cells were collected 24 h post-
anaesthetic exposure and used to determine HIF-1-a/VEGF and
HIF-1-a/Ki67 levels through immunocytochemistry and cell
proliferation rates with an MTT assay. Propofol at 4mgml 1
effectively blocked isoflurane-induced HIF-1a expression and the
associated expression of VEGF (Figure 3A and C) and Ki67
(Figure 3B and D), which are well-established markers for
angiogenensis and active cellular proliferation, respectively. A
similar inhibitory effect was also observed with HIF-1a-specific
siRNA, which selectively blocked isoflurane-induced HIF-1a
overexpression (HIF-1a level decreased from 2.47±0.42 of
isoflurane exposure vs 1 of NC to 0.74±0.11 of isoflurane plus
siRNA exposure vs 1 of NC, Po0.001; Supplementary Figure 1).
Both VEGF (Figure 3A) and Ki67 levels (Figure 3B) were reduced
as a result of HIF-1a inhibition.
Isoflurane promoted cell cycle progression and cell proliferation,
which was inhibited by propfol and HIF-1a siRNA. We next
assessed the cell cycle progression and cell proliferation after
exposure to isoflurane. Enhanced cyclin D and cyclin E expression
in PC3 cells was found after being exposed to isoflurane, and
co-localization of HIF-1 a/cyclin D or HIF-1 a/cyclin E was noted
(Figure 4A–D); the treatments with either propfol or HIF-1a siRNA
abolished these effects (Figure 4A–D) when compared with that
treated with isoflorane. Cell viability was decreased from 1.41±0.12
(relative to control) with isoflurane exposure to 1.10±0.20 with
isoflurane plus propofol exposure (P¼ 0.012) (Figure 4E).
Isoflurane induced resistance to the chemotherapeutic agent
docetaxel in PC3 cells, which could be reversed by propofol and
HIF-1a-specific siRNA. The next step was to determine whether
isoflurane and propofol had any effects on the efficacy of anti-
mitotic chemotherapy drug commonly used in prostate cancer,
DTX. To determine whether the efficacy of DTX was altered with
changing HIF-1a expression, PC3 cells were first exposed for 2 h to
isoflurane, isoflurane plus propofol, or isoflurane in siRNA pre-
treated cells followed by treatment with DTX for 24 h. Cells were
harvested immediately after DTX treatment for immunocytochem-
istry and western blotting. It was observed that DTX was less
effective in inhibiting active mitosis in isoflurane-exposed PC3
cells, evident by the 58.53±7.32% of actively dividing cells (Ki67
positive) when compared with the DTX treatment alone
(25.61±6.71%, Po0.001), or to the cells that were treated with
propofol plus isoflurane (17.96±11.56%, Po0.001) (Figure 5A and B)
and to the cells that were treated with isoflurane plus siRNA
(27.52±8.88%, Po0.001; Figure 5A). This was further supported
by an MTT assay, which showed that isoflurane-pre-treated PC3
cells had a higher proliferation rate after DTX challenge, when
compared with non-pre-treated PC3 cells (0.36±0.03-fold of naı¨ve
vs 0.13±0.05-fold of naive, P¼ 0.006; Figure 5B). With addition of
propofol to isoflurane for the pre-treatment, the proliferation rate
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was decreased (0.18±0.04-fold of naı¨ve vs 0.36±0.03-fold of
naı¨ve, P¼ 0.047). Furthermore, cytochrome c, a marker for cellular
injury, was lower in the isoflurane and DTX co-treated cells when
compared with DTX alone, isoflurane-propofol–DTX co-treated
and isoflurane, siRNA and DTX groups (Figure 5C). This was
coupled with overexpression of the anti-apoptotic Bcl-2 protein in
cells with 2% isoflurane exposure and DTX treatment compared
with cells with DTX treatment alone (2.54±0.69-fold of naı¨ve vs
0.45±0.23-fold of naive, Po0.001; Figure 5D, left panel and
2.49±0.50-fold of naı¨ve vs 0.44±0.19-fold of naive, Po0.001;
Figure 5D, right panel). The overexpression of Bcl-2 was prevented
with SiRNA pre-treatment (2.54±0.69-fold of naı¨ve vs 0.25±0.17-
fold of naive, Po0.001; Figure 5D, left panel) and propofol pre-
treatment (2.49±0.50-fold of naı¨ve vs 0.33±0.12-fold of naive,
Po0.001; Figure 5D, right panel).
Phosphorylation of Akt, but not ERK, played an important role
in the alteration of HIF-1a expression induced by isoflurane or
propofol. Collectively, these experiments established that isoflur-
ane promotes cancer cell growth and survival in the face of various
challenges via activation of HIF-1a and upregulation of anti-
apoptotic protein BcL-2. Next, we determined the molecular basis
underlying isoflurane-induced upregulation of HIF-1a. We inves-
tigated whether the PI3K/Akt/mTOR pathway and MAPK/ERK
pathways were involved in the isoflurane-induced upregulation
and propofol-induced downregulation of HIF-1a. PC3 cells were
treated with either a PI3K inhibitor (LY294002) or an MAPK/ERK
(MEK) 1/2 inhibitor (U0126) overnight, then were exposed to
either isoflurane or isoflurane and propofol for 2 h. Twenty-four
hours later, the cells were harvested for western blotting and
protein levels of HIF-1a, phosphorylated Akt (p-Akt) and
phosphorylated ERK (p-ERK) were investigated. Phosphorylation
of the kinase Akt, but not ERK 1/2, appear to play the dominant
role in isoflurane-induced HIF-1a overexpression. LY294002
blocked HIF-1a overexpression showing a significant decrease in
the inhibitor plus isoflurane group when compared with the
isoflurane group alone (1.14±0.38-fold of naı¨ve vs 4.16±1.02-fold
of naive, Po0.001 Figure 6A), but no significant changes when
compared with the group that had also received propofol
(1.14±0.38-fold of naı¨ve vs1.29±0.61-fold of naive, P¼ 1;
Figure 6A). By contrast, the MEK 1/2 inhibitor, U0126, had no
significant effect on HIF-1a expression with the inhibitor plus
isoflurane group showing no significant difference to the isoflurane
group alone (3.13±0.67-fold of naı¨ve vs 4.16±1.02-fold of naive,
P¼ 0.443; Figure 6A), but did display a significantly higher
amount of HIF-1a protein relative to the group that received
isoflurane plus propofol (3.13±0.67-fold of naı¨ve vs 1.29±0.61-
fold of naı¨ve, p¼ 0.035; Figure 6A). It was further shown that
isoflurane and propofol had opposite effects on the phosphoryla-
tion of Akt kinase with isoflurane showing significantly higher
amounts of p-Akt when compared to the naı¨ve control
(2.98±0.57-fold of naı¨ve Po0.001; Figure 6B), an effect abolished
by pre-treatment with LY294002 (2.98±0.57-fold of naı¨ve vs
1.29±0.37, P¼ 0.002; Figure 6B) and co-intervention with
propofol (2.98±0.57-fold of naı¨ve vs 1.68±0.63, P¼ 0.02;
Figure 6B). In terms of the phosphorylation of ERK, isoflurane
alone showed an increasing trend compared to the naı¨ve control
but no significant change (1.71±0.52-fold of naı¨ve, P¼ 0.081;
Figure 6C). However, there was a significant decrease in the
propofol (0.95±0.26-fold of naı¨ve vs 1.71±0.52, P¼ 0.048;
Figure 6C) and inhibitor groups (0.79±0.27-fold of naı¨ve vs
1.71±0.52, P¼ 0.013; Figure 6C) when compared to isoflurane
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alone. In order to distinguish the potential different effects of
isoflurane and propofol exposure on phosphorylation of Akt, PC3
cells were exposed to 2% isoflurane or 4 mgml 1 propofol alone
for 2 h. Then protein samples were harvested at 0, 2, 4, 8 and 24 h
after anaesthetics exposure. Isoflurane exposure induced a marked
increase in p-Akt in a time-dependent manner (Figure 6D).
Conversely, propofol exposure induced a marked decrease in p-Akt
for initial 2 h after exposure and then return to a normal level
which is likely due to positive feedback mechanism (Figure 6E).
From these findings, it can be speculated that propofol prevented
isoflurane-induced HIF-1a overexpression by antagonising phos-
phorylation of Akt, although this inhibition could also partly be
due to the decrease in the phosphorylation observed in ERK.
Isoflurane enhanced PC3 cell migration and invasion which was
reversed by propofol and HIF-1a-specific siRNA. Enhanced
MMP-2 and MMP-9 production was found in the cell medium
treated with isoflurane, but not with the other treatments including
propofol exposure (Figure 7A and B). Consistent with these results,
data obtained from the scratch assay showed that isoflurane
treatment significantly accelerated gap closure compared with
controls at 24 h after a scratch was made (Figure 7C and D). Either
propofol or HIF-1a siRNA suppressed these effects (Figure 7C and D).
DISCUSSION
In this study using cultured prostate cancer PC3 cells, we show that
isoflurane, one of the most commonly used inhaled anaesthetics,
activates HIF-1a expression in an oxygen-independent manner
which, in turn, enhances cancer cell proliferation and migration
together with the reinforcement of chemotherapy resistance. In
contrast, propofol, the most commonly used intravenous anaes-
thetic, had no effect on HIF-1a expression in PC3 cells when used
alone but it was capable of inhibiting chemical- or isoflurane-
induced HIF-1a overexpression.
HIF-1a activation in cancer has been heavily implicated in
disease progression. Elevated levels have been found in a variety
of human cancers (Talks et al, 2000) and correlated with tumour
growth, vascularisation, metastasis and hence poor prognosis
(Semenza, 2012). As transcription factors directly govern the
expression of hundreds of genes, HIFs orchestrate crucial steps
in tumorigenesis including angiogenesis, metabolic reprogram-
ming, proliferation, metastasis and invasion, thus proving an
attractive target for cancer therapy (Semenza, 2010; Semenza,
2012). Intuitively, it follows that exposure to a stimulus that
further boosts HIF-1a levels and its associated repertoire of
downstream activities in cancer cells would add fuel to the
flames.
Isoflurane exposure induced a more than three-fold rise in
HIF-1a level and did so in a dose-dependent manner, this was
sustained and continued as long as 24 h afterward. In contrast,
hypoxia induced only a transient overexpression of HIF-1a in
renal cancer or normal cells in previous reports (Ma et al, 2009).
As demonstrated clearly in this study, HIF-1a was seen to
translocate from cytoplasm to nucleus where it assumes its role
as a transcription factor. There was also a concomitant rise in the
expression of its downstream genes including VEGF, a protein with
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a critical role in establishing neovascularization to boost a tumour’s
supply of oxygen and nutrients, and Ki67, a nuclear protein
required for cellular proliferation that is widely used as a clinical
prognostic indicator. With the introduction of a HIF-1a-specific
siRNA, the increased expression of these two proteins in response
to isoflurane exposure was no longer seen. Considering the
widespread use of volatile anaesthetics in clinical practice, it is
rational to postulate that, during cancer surgery, cancer cells gain
enhanced malignant transformation after exposure to isoflurane as
a result of activation of HIF-1a. The current findings may tie up
with the clinical observation that general anaesthesia was
associated with increased risk of cancer recurrence in prostate
cancer (Biki et al, 2008a).
One of the consequences of the rapid and uncontrolled
proliferation that characterises cancer cells is that the developing
tumour soon outstrips its blood supply, leading to hypoxia that is
most severe at the tumour’s inner core. Here, HIF-1a levels are
driven upward as the oxygen-dependent reactions that permit
proteasomal degradation are limited. But HIF-1a levels may also
rise independently of oxygen via loss-of-function mutations to
tumour suppressor genes, such as VHL and PTEN, or gain-of-
function mutations to proto-oncogenes, or by activation of the
PI3K/Akt/mTOR and MAPK/ERK pathways involved in neosynth-
esis of HIF-1a protein (Jiang et al, 2001). Various growth factors
and cytokines including insulin, insulin-like growth factor,
epidermal growth factor and interleukin-2 are known to activate
these pathways and subsequently increase the rate of synthesis of
HIF-1a protein (Semenza, 2003a). To determine the contribution
of PI3K/Akt/mTOR and MAPK/ERK pathways in isoflurane-
induced upregulation of HIF-1a, we treated PC3 cells with the
PI3K inhibitor LY294002 or the MAPK/ERK 1/2 inhibitor U0126
before exposure to isoflurane and found that the PI3K inhibitor
abrogated the rise of HIF-1a, whereas the MEK 1/2 inhibitor had
little effect. High levels of phosphorylated Akt were also seen in
response to isoflurane exposure, an effect abolished by pre-
treatment with LY294002. Our data obtained from prostate cancer
cells and renal carcinoma cells (Benzonana et al, 2013) indicate
that isoflurane upregulates the synthesis of HIF-1a via the PI3K/
Akt/mTOR pathway. In addition, other previous studies have
demonstrated that isoflurane could affect HIF-1a expression in
other cell lines, such as hepatocellular carcinoma Hep3B cells (Li
et al, 2006). All these studies provide strong evidence for the
generality of isoflurane on HIF-1 expression in cancer cells. Hence,
the multi-cellular effects including HIF-1a, Akt and their cascades
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afforded by isoflurane ultimately promote cancer cell survival and
growth toward anti-cancer treatment resistance.
HIFs have also been linked with chemoresistance. HIF-1a
regulates transcription of at least two genes, namely ABCB1 and
ABCG2, belonging to the family of multi-specific drug efflux
transporters that are responsible for the observed resistance to a
widely used variety of cytotoxic agents such as taxanes,
doxorubicin and Vinca alkaloids (Monti and Gariboldi, 2011).
The HIF-regulated metabolic shift from oxidative to glycolytic
mode and induction of carbonic anhydrase also hinders the
delivery of these drugs to their intracellular targets (Greijer et al,
2005). We found that PC3 cells exposed to isoflurane showed
significantly less response to the anti-mitotic chemotherapy agent,
docetaxel, than naı¨ve controls, as evidenced by a higher
proliferation rate, a higher proportion of cells seen to be in active
mitosis, lower levels of the cell injury marker cytochrome c and
overexpression of the anti-apoptotic protein Bcl-2. This resistance
diminished when a HIF-1a-specific siRNA was introduced,
supporting the expectation that this effect is mediated through
isoflurane’s upregulation of HIF-1a.
Propofol is widely used in clinical practice, largely due to its
advantageous pharmacokinetic profile. It has been reported that
propofol reduced the invasive capability of human cancer
cells by inhibiting the formation of actin stress fibres and focal
adhesion in HeLa human cervix carcinoma cells and inhibited
pulmonary metastasis in a murine model of osteosarcoma
(Mammoto et al, 2002), and enhanced the activity of cytotoxic
T cells in mice (Kushida et al, 2007) and humans (Ren et al,
2010). In another distinguished trial, serum from patients
receiving propofol/ paravertebral anaesthesia for breast cancer
surgery inhibited proliferation of cultured breast cancer cell
compared with serum from patients receiving sevoflurane/opioid
anaesthesia-analgesia (Deegan et al, 2009). In addition, there are
studies showing that propofol can negate the ‘bad’ or ‘good’
effects resulting from volatile anaesthetics exposure (Smul et al,
2010; Zhang et al, 2011) and that propofol suppresses HIF-1a
protein synthesis (Takabuchi et al, 2004b) as well as its
downstream effects (Yeh et al, 2011).
Our data demonstrate that propofol inhibits upregulation of
HIF-1a by isoflurane as well as by copper chloride and hypoxia.
Furthermore, it suppressed the rise of VEGF and Ki67 that had
been observed after exposure to isoflurane and protected against
isoflurane-induced resistance to docetaxel. These findings add
further support to the growing evidence that propofol has
properties against the malignant activities of cancer cells. Taken
together with the experiments showing that propofol co-treatment
reduces phosphorylation of Akt and suppresses upregulation of
HIF-1a by known inducers, it may be that propofol’s inhibitory
action on the PI3K pathway and HIF-1a underpins its observed
anti-tumour effects. However, while there are data indicating that
the inhibition of HIF-1a by propofol results from factors affecting
its synthesis rather than its post-translational stabilisation
(Takabuchi et al, 2004a; Tanaka et al, 2010), there is a relative
paucity of detail on this subject which future work needs to
elucidate. Interestingly, PC3 cells are known to have high p-Akt
level due to loss of PTEN (Shukla et al, 2007). Our results show
that isofluorane exposure induced even more p-Akt expression,
which indicated that isofluorane could further enhance the tumour
malignancy through increasing p-AKT to even higher expression
level but this warrants further study.
Clinical studies comparing the effect of general anaesthesia vs
the use of epidural anaesthesia on cancer recurrence have drawn
different conclusions, and recent review articles have found the
discrepancies too great to support a change in clinical practice
at this time (Heaney and Buggy, 2012; Tavare et al, 2012). Our
study demonstrates the importance of such studies not only
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differentiating between general and epidural anaesthesia but also
among the type of general anaesthetic agents used.
Despite conducting our experiments using anaesthetics, doses
and exposure periods that are clinically appropriate, in vitro studies
are clearly limited in their ability to model tumour responses or the
delivery of the anaesthetics to different tissues in vivo. For example,
while we have shown propofol to suppress isoflurane’s deleterious
effects on cancer cell activity in vitro, we do not know whether the
single dose given at induction in clinical practice is sufficient to
protect against the far lengthier course of isoflurane administration
or whether such protection could only be afforded by a sustained
concentration of propofol over the course of the entire operation.
Future work is needed to characterise the interaction between these
two anaesthetics in a way that accurately reflects the timing and
manner in which they are used clinically. This inevitably requires
in vivo experiments or clinical trials to accurately account for the
tumour’s activities within its host and replicate the factors involved
during surgery. In addition, in clinical settings, patients’ conditions
including anaesthetic regimens that are implemented during
surgery are rather complex. Our augments would be much
stronger if change of activation of signaling pathways is observed
in xenograft tumours after being exposed to different anaesthetics,
this certainly warrants further investigations in future studies.
Simply, combined anaesthetics including opiods are essential for
general anaesthesia. A previous elegant study showed that
morphine-induced epidermal growth factor receptor phosphoryla-
tion leads to downstream MAPK/ERK and Akt phosphorylation
and increased invasion in human lung cancer cultures (Fujioka
et al, 2011). Morphine has also been reported in vitro and in vivo to
promote cell proliferation and angiogenesis through cellular
survival signals in human breast cancer cells (Gupta et al, 2002),
whereas Fentanyl was found to activate HIF-1a in neuroblastoma
cells (Daijo et al, 2011). Furthermore, the genetic and phenotypic
heterogeneity of cancer as a disease makes it highly likely that
different cancer types will respond to anaesthetics in different
ways, making it important to conduct such experiments using a
variety of tumour types which are ongoing in the authors’
laboratory.
The underlying molecular mechanism that isoflurane activates
the PI3K/Akt pathway remains incompletely understood. It was
demonstrated that isoflurane may activate the PI3K/Akt pathway
by enhancing cytosolic calcium concentration via activation of
inositol triphosphate receptors (Bickler and Fahlman, 2006; Bickler
and Fahlman, 2010), with altered expression profile in genes
regulating growth and survival. This observation is consistent with
our studies. In addition, cytosolic calcium concentration has been
demonstrated to be involved on cancer cell cycle progression and
malignancy (Taylor et al, 2008). Furthermore, both isoflurane and
propofol interact and activate GABA receptors (Garcia et al, 2010),
but different from propofol, isoflurane inhibits NMDA receptor
(Tsuda, 2010) and has been shown to significantly affect cytosolic
calcium concentration (Xin et al, 2005). This may help to explain
the notable difference between isoflurane and propofol on cancer
cell growth and malignancy as observed in our studies. General
anaesthetics have been increasingly shown to have dual effects of
cytoprotection and cytotoxicity (Wei and Inan, 2013). Again,
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calcium has been shown to be involved: low dose for short duration
is beneficial and promotes cell growth and proliferation, which
induce endogenous cytoprotective mechanisms via moderate
calcium release (Zuo, 2012; Wei and Inan, 2013). On the other
hand, anaesthetics at high concentrations for prolonged duration is
toxic to the cells and cause cell death via excessive and abnormal
calcium release (Wei, 2011). Based on this, the association between
general anaesthetics such as isoflurane and propofol, their duration
and dose should be investigated in our future studies.
In conclusion, we have shown that isoflurane upregulates HIF-
1a in prostate cancer cells via the PI3K/AKT/mTOR pathway,
leading to concomitant increases in markers and mediators of
angiogenesis, proliferation and chemoresistance. Meanwhile, the
addition of propofol to isoflurane treatment suppresses all of those
effects and appears to do so by antagonising phosphorylation of
Akt. This study builds on the so far, primitive body of preclinical
evidence that anaesthetics directly interfere with cancer cell biology
and indicates that two of the most commonly used agents have
disparate effects on HIF-1a and its associated actions promoting
malignant progression. Clinical studies examining the impact of
anaesthetics on cancer recurrence should now account for this in
their trial design or data interpretation and future work should
begin to characterise the effects of common combinations of
anaesthetics in a variety of tumour models that replicate the
operative period as accurately as possible.
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